Biosimilar ustekinumab CT-P43

Czech version

Authors: M. Lukáš
Authors‘ workplace: Klinické a výzkumné centrum pro střevní záněty, Klinické centrum ISCARE a. s. a 1. LF UK v Praze
Published in: Gastroent Hepatol 2025; 79(1): 55-56
Category: Drug Profile
doi: https://doi.org/10.48095/ccgh202555

Sources

1. ClinicalTrial.gov. Study to Compare PK and Safety of Subcutaneous Injection of Ustekinumab and CT-P43 in Healthy Subjects. 2021 [online]. Dostupné z: https: //clinicaltrials.gov/study/NCT04428814?term=CT-P43& checkSpell=false&rank=2.

2. ClinicalTrial.gov. A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque Psoriasis. 2023 [online]. Dostupné z: https: //clinicaltrials.gov/study/NCT04673786?term=CT-P43&checkSpell=false&rank=1.

3. Papp KA, Lebwohl MG, Thaci D et al. Efficacy and safety of candidate biosimilar CT-P43 versus originator ustekinumab in moderate to severe plaque psoriasis: 28 week results of a randomized, active controlled, double blind, phase III study. BioDrugs 2024; 38 (1): 121–131. doi: 10.1007/s40259-023-00630-5.

Korespondenční autor

prof. MUDr. Milan Lukáš, CSc., AGAF

Klinické a výzkumné centrum pro střevní záněty

Klinické centrum ISCARE a. s. a 1. LF UK v Praze

Českomoravská 19

190 00 Praha 9

milan.lukas@email.cz